[Market Focus] Hanmi Pharmaceutical Surges on News of Novel Obesity Drug Presentation in US

Hanmi Pharmaceutical is showing strong performance. This is believed to be influenced by news that the company will present research results on next-generation obesity treatments at the American Diabetes Association (ADA 2025).

As of 1:52 p.m. on June 10, Hanmi Pharmaceutical was trading at 311,000 won, up 6.32% from the previous day.

Hanmi Pharmaceutical plans to participate in ADA 2025, which will be held in Chicago, United States, from June 20 to June 23. The company will present preclinical and clinical research results on its "next-generation triple agonist for obesity treatment (LA-GLP/GIP/GCG, HM15275)" and "novel obesity treatment (LA-UCN2, HM17321)."

The research results to be disclosed include a total of six items: ▲ Phase 1 clinical results for HM15275 ▲ Potent weight loss efficacy and mechanism of action of HM15275 in obese animal models ▲ Mechanism by which HM15275 improves the quality of weight loss compared to tirzepatide (Zepbound) ▲ Weight loss and differentiated body composition improvement effects of HM17321 ▲ Improved blood glucose control with HM17321 ▲ Synergistic effects on body composition improvement when HM15275 and HM17321 are used in combination.

In particular, the Phase 1 clinical results for HM15275 will be presented for the first time at ADA 2025. HM15275 and HM17321 are considered the next-generation pipeline following the innovation of "efeglenatide," which is targeted for commercialization in the second half of next year. Each is evaluated as having the potential to be developed as a "best-in-class" and "first-in-class" drug, respectively, in the field of obesity treatment.

Currently, Hanmi Pharmaceutical is accelerating the development of next-generation obesity drugs with the goal of providing "patient-tailored solutions" across the entire spectrum of obesity treatment. The company aims to secure a number of differentiated drug candidates that address the limitations of existing obesity treatments by precisely reflecting the characteristics and therapeutic needs of a wide range of obesity patient groups.